Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVEREST: Zorifertinib vs SoC EGFR-TKI in EGFR+ NSCLC with CNS Metastases
NCT03653546Phase 3Completed
- Sponsor
- Alpha Biopharma
- Start
- Oct 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of zorifertinib in non-small cell lung cancer (NSCLC) and central nervous system metastases (2 arms), sponsored by Alpha Biopharma. Primary endpoint: Progression-Free Survival at 48 months. Started Oct 2018; status: completed.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)central nervous system metastases
Beyond the preview
Go deeper on NCT03653546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653546.